Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

Stacks

UK peptide stacks: editorial guides and named bundles

Two ways to think about peptide combinations. Editorial stack guides discuss which evidence-graded compounds target the same goal, and what the literature does and does not show about combining them. Named retailer bundles list the most common multi-compound branded stacks UK research peptide retailers sell. We do not recommend specific stacks for specific people. A combination of peptides should be discussed with a UK-registered prescriber.

Editorial stack guides by goal

Named research-peptide bundles (UK retailers)

Wolverine Stack

BPC-157 + TB-500

The Wolverine Stack is the most common named stack in the UK research peptide segment. It pairs BPC-157 (a 15-residue gastric-derived peptide) with TB-500 (a synthetic fragment of Thymosin Beta-4). Both are research compounds with preclinical literature on tissue protection and cell migration. No human RCT data is published for either.

Read the comparison

Hulk Stack

Ipamorelin + CJC-1295

The Hulk Stack pairs a ghrelin-receptor agonist (Ipamorelin) with a GHRH analogue (CJC-1295). The pairing targets two distinct GH-release pathways simultaneously. Researchers report larger preclinical GH release than either alone. Both are research-tier in the UK.

Read the comparison

KLOW Stack

GHK-Cu + Variable per retailer

The KLOW Stack is a multi-component research-peptide blend sold by several UK retailers under that brand name. Composition varies by retailer (commonly GHK-Cu plus complementary peptides for skin, liver, and recovery). Documenting per-retailer composition is the only honest framing.

Read the comparison

Glow Stack

GHK-Cu + Argireline (Acetyl hexapeptide-3) + Palmitoyl tripeptides

The Glow Stack is a retailer-branded cosmetic-peptide blend for skin appearance. Typical composition: GHK-Cu (copper tripeptide), Argireline (acetyl hexapeptide-3), and one or more palmitoyl-tripeptides. UK research-peptide retailers ship the injectable variant. Cosmetic retailers ship the topical variant.

Read the comparison

GH Stack

Ipamorelin + CJC-1295 + Sermorelin + Tesamorelin

GH Stack is the generic class name for any GH-secretagogue research-peptide combination. The most common variant is the Hulk Stack (Ipamorelin plus CJC-1295). Other variants include Tesamorelin plus Ipamorelin and GHRP-2 plus Sermorelin. All UK research-tier.

Read the comparison

Healing Stack

BPC-157 + TB-500 + KPV

The Healing Stack expands the Wolverine Stack by adding KPV (the C-terminal tripeptide of alpha-MSH). KPV adds anti-inflammatory preclinical signal to the BPC-157 plus TB-500 tissue-repair pairing. All three are research-tier in the UK.

Read the comparison

Longevity Stack

Epitalon + MOTS-c + NAD+

The Longevity Stack targets mitochondrial function and the pineal-pituitary axis. Typical composition: Epitalon (Russian-research tetrapeptide), MOTS-c (mitochondrial-derived peptide), and NAD+ (coenzyme, not a peptide). All three are sold by UK research peptide retailers under research-use-only framing.

Read the comparison

Sleep Stack

DSIP + Epitalon

The Sleep Stack is a smaller research-peptide pairing focused on delta-wave sleep and pineal-axis regulation. Typical composition: DSIP (Delta Sleep-Inducing Peptide) and Epitalon. Both are research-tier. The literature is preclinical and the function of DSIP remains incompletely characterised after four decades of research.

Read the comparison

Sexual Health Stack

PT-141 (Bremelanotide) + Kisspeptin

The Sexual Health Stack pairs PT-141 (Bremelanotide, FDA-approved in the US for premenopausal HSDD as Vyleesi) with Kisspeptin (research compound under active UK clinical investigation at Imperial College London). UK regulatory status for both is research-tier outside of clinical trial enrolment.

Read the comparison

GLP-1 Companion Stack

AOD-9604 + MOTS-c

The GLP-1 Companion Stack covers research-peptide compounds that some researchers explore alongside licensed GLP-1 weight-management medications. It is NOT a replacement for the licensed medication, NOT a clinical protocol, and NOT a recommendation. Your UK prescriber decides on the licensed medication. The research peptides discussed here are research-tier.

Read the comparison

Cognitive Stack

Semax + Selank

The Cognitive Stack pairs two Russian-research nootropic peptides developed at the Institute of Molecular Genetics in Moscow: Semax (ACTH 4-10 heptapeptide) and Selank (tuftsin-derived heptapeptide). Both are licensed Russian Federation pharmaceuticals for specific neurological indications. UK status: research-tier only.

Read the comparison

Recovery Stack

BPC-157 + TB-500 + IGF-1 LR3

The Recovery Stack expands the Wolverine Stack by adding IGF-1 LR3 (Long-R3 IGF-1, a long-acting IGF-1 analogue). This adds anabolic-pathway signal to the tissue-repair pairing. All three are research-tier in the UK.

Read the comparison

Next steps

Compare prices on individual compounds, or check which UK retailers we have vetted before you buy. New to handling research vials? See our reconstitution kit guide. Research use only, not for human or animal consumption.

Popular on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-06-04T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.